<DOC>
	<DOCNO>NCT00176046</DOCNO>
	<brief_summary>The purpose feasibility study identify appropriate surrogate parameter randomize study examine efficacy complementary therapy extract viscum album ( Iscador P ) patient breast cancer .</brief_summary>
	<brief_title>Mistletoe Extract Early Advanced Breast Cancer , A Feasibility Study</brief_title>
	<detailed_description>The study consist three part . Part 1 prospective non-randomized feasibility study patient breast cancer primary surgery chemotherapy endocrine therapy compare blood count , lymphocytes , quality life local general side effect group Part 2 prospective randomize feasibility study wait list three month compare change quality life , depression , diurnal cortisol profile expression zeta-chains T- NK-cells three month treatment wait patient two different stratum ( early breast cancer UICC I/II metastatic breast cancer ) Part 3 consist two follow-up period 12 month respective . Patients may choose continue , quit restart mistletoe treatment upon decision , endpoint part 2 evaluate every 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Viscum album peptide</mesh_term>
	<criteria>breast cancer desire additional therapy mistletoe extract contraindication therapy mistletoe extract ( allergy , tuberculosis , hyperthyreosis , acute infectious disease , intracranial pressure case tumor metastasis ) current medication glucocorticoid immunosuppressive therapy concomitant complementary therapy prior therapy mistletoe extract &gt; 2 year last 6 month karnofskyIndex &lt; 60</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>mistletoe</keyword>
	<keyword>complementary therapy</keyword>
	<keyword>quality life</keyword>
	<keyword>immune function</keyword>
	<keyword>breast cancer ( UICC stage I/II )</keyword>
</DOC>